Ignite Creation Date:
2024-05-06 @ 7:48 PM
Last Modification Date:
2024-10-26 @ 3:14 PM
Study NCT ID:
NCT06141109
Status:
RECRUITING
Last Update Posted:
2023-11-21
First Post:
2023-11-09
Brief Title:
Treatment of MB07133 Plus Sintilimab in Patients With Hepatocellular Carcinoma
Sponsor:
Xian Xintong Pharmaceutical Research CoLtd
Organization:
Xian Xintong Pharmaceutical Research CoLtd
Study Overview
Official Title:
Safety Tolerability and Efficacy of MB07133 Plus Sintilimab in Patients With Hepatocellular Carcinomaa Phase 12a Study
Status:
RECRUITING
Status Verified Date:
2023-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
MB07133
Brief Summary:
An open-label multi-dose clinical trial design was used to investigate the combination of MB07133 injection combined with Sintilimab in the treatment of primary liver cancer in phase IIIa studies including two phases of dose escalation and dose expansionin order to evaluate the safety and efficacy of MB07133 injection combined with Sintilimab
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None